You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

21 Results
Drug
Other Name(s): Temodal®
Aug 2025
Drug
Other Name(s): Mekinist®
Jun 2025
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Funding:
ODB - General Benefit
    temozolomide
Aug 2025
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    trametinib - As monotherapy in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, according to specific criteria
Jun 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Jul 2025
Regimen
Cancer Type:
Central Nervous System
Intent: Adjuvant
Funding:
ODB - General Benefit
    temozolomide
Aug 2025
Drug
Other Name(s): Lonsurf®
Nov 2024
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    tamoxifen
Sep 2025
Drug
Other Name(s): Tukysa™
Feb 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Palliative
Funding:
Exceptional Access Program
    trifluridine / tipiracil - In combination with bevacizumab for treatment of metastatic colorectal cancer, according to clinical criteria
New Drug Funding Program
    Bevacizumab (Biosimilar) - In Combination with Trifluridine and Tipiracil for Previously Treated Metastatic Colorectal Cancer
Nov 2024
Drug
Other Name(s): Kimmtrak®
Oct 2025

Pages